Therefore, our data indicated that high susceptibility to TRAIL of metastatic cancer cells is associated with up-regulation of DR5 and concurrent down-regulation of c-FLIP and Mcl-1 by TRAIL treatment. This evidence concerns the gene TNFRSF10B and cancer.